DrugBiological
Timdarpacept clinical trials
Also written IMM01.
Keep track of what changes. Save the timdarpacept studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2022 | 3 |
| 2024 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 6
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (6) · Immunis, Inc. (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses timdarpacept is read from its arms, and is right about nine times in ten.
Testing it · 8
- IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)RecruitingPhase 3ImmuneOnco Biopharmaceuticals (Shanghai) Inc.NCT06647862Written as IMM01
- A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid TumorsNot yet recruitingPhase 1/2ImmuneOnco Biopharmaceuticals (Shanghai) Inc.NCT07170787Written as IMM01
- A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin LymphomaNot yet recruitingPhase 3ImmuneOnco Biopharmaceuticals (Shanghai) Inc.NCT06465446Written as IMM01
- A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeRecruitingPhase 1/2ImmuneOnco Biopharmaceuticals (Shanghai) Inc.NCT05140811Written as IMM01
- Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.CompletedPhase 1/2Immunis, Inc.NCT05211986Written as IMM01-STEM
- Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle WeaknessActive, not recruitingPhase 2Immunis, Inc.NCT06600581Written as IMM01-STEM
- Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic MalignancyTerminatedPhase 1ImmuneOnco Biopharmaceuticals (Shanghai) Inc.NCT05860075Written as IMM01
- Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and LymphomasStatus unknownPhase 1/2ImmuneOnco Biopharmaceuticals (Shanghai) Inc.NCT05833984Written as IMM01
Codes
What other systems call timdarpacept · ClinicalTrials.gg INT015206
- UNII (FDA) 664WQ5KSP8TIMDARPACEPTOne source FDA
- NCI Thesaurus C199120TimdarpaceptOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 664WQ5KSP8 | TIMDARPACEPT | One source FDA |
| NCI Thesaurus | C199120 | Timdarpacept | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.